zurück

Sofosbuvir / velpatasvir (new indication: chronic hepatitis C; patients aged ≥ 3 - 6 years)

Subject:

  • Active Substance: Sofosbuvir
  • Name: Epclusa®
  • Therapeutic area: Chronic hepatitis C
  • Pharmaceutical company: Gilead Sciences GmbH

Time table:

  • Start: 15.02.2022
  • Final decision by G-BA: 04.08.2022

Final decision:

  • No additional benefit proved